ArticleInfection & chemotherapy2026
Clinical Outcomes of Tenofovir, Lamivudine, and Dolutegravir in Treatment-Naïve versus Treatment-Experienced HIV Patients: A Single-Center Retrospective Cohort Study in Indonesia.
Article in Infection & chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization recommended dolutegravir (DTG)-based antiretroviral therapy (ART) as first- and second-line treatment for people living with HIV (PLHIV) in 2018. Given its widespread use across diverse patient populations, ongoing evaluation of the real-world effectiveness and tolerability of DTG-based ART particularly across treatment-naïve (TN) and treatment-experienced (TE) patients remains essential to inform routine clinical practice. MATERIALS AND
methodsThis retrospective cohort study included PLHIV receiving tenofovir, lamivudine, and dolutegravir (TLD) at a tertiary referral hospital. Patients were classified as TN or TE. Outcomes at 12 months included virological response, immunological status, weight change, and toxicity/adverse events. Statistical analyses included descriptive statistics, chi-square tests for categorical variables, multivariable Poisson regression was performed for the immunological status to estimate adjusted relative risks (aRR), and Mann-Whitney
resultsA total of 147 participants were included in the analysis. The mean age was 37.9±10.5 years in the TN group and 41.2±9.1 years in the TE group, with males predominating in both groups (75.0%
conclusionAfter 12 months of TLD therapy, no significant differences were observed between TN and TE HIV patients in virological response, immunological status, or toxicity/adverse events. A significant difference was observed in weight change, with greater weight gain among TN patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.